Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING BIGLYCAN AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2019/143219
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating diabetes, containing biglycan as an active ingredient. According to the present invention, biglycan induces blood glucose lowering through AMPK phosphorylation and an increase in glucose uptake, and thus is useful as an agent for treating insulin-resistant diabetes.
More Like This:
Inventors:
KIM HYEON SOO (KR)
Application Number:
PCT/KR2019/000867
Publication Date:
July 25, 2019
Filing Date:
January 22, 2019
Export Citation:
Assignee:
UNIV KOREA RES & BUS FOUND (KR)
International Classes:
A61K31/726; A23L33/10; A23L33/125; A61P3/10
Domestic Patent References:
| WO1993010808A1 | 1993-06-10 |
Other References:
BOLTON, K.: "The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes", BIOLOGIES: TARGETS & THERAPY, vol. 6, 30 March 2012 (2012-03-30), pages 67 - 72, XP055624923
KIM, J.: "Enhanced biglycan gene expression in the adipose tissues of obese women and its association with obesity-related genes and metabolic parameters", SCIENTIFIC REPORTS, vol. 6, no. 30609, 28 July 2016 (2016-07-28), pages 1 - 11, XP055624927
HIUKKA, A. ET AL.: "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan", DIABETES, vol. 58, no. 9, September 2009 (2009-09-01), pages 2018 - 2026, XP055624931
WU, Y.-F.: "High glucose alters tendon homeostasis through downregulation of the AMPK/Egr1 pathway", SCIENTIFIC REPORTS, vol. 7, no. 44199, 7 March 2017 (2017-03-07), pages 1 - 12, XP055624936
KIM, J.: "Enhanced biglycan gene expression in the adipose tissues of obese women and its association with obesity-related genes and metabolic parameters", SCIENTIFIC REPORTS, vol. 6, no. 30609, 28 July 2016 (2016-07-28), pages 1 - 11, XP055624927
HIUKKA, A. ET AL.: "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan", DIABETES, vol. 58, no. 9, September 2009 (2009-09-01), pages 2018 - 2026, XP055624931
WU, Y.-F.: "High glucose alters tendon homeostasis through downregulation of the AMPK/Egr1 pathway", SCIENTIFIC REPORTS, vol. 7, no. 44199, 7 March 2017 (2017-03-07), pages 1 - 12, XP055624936
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF:
Previous Patent: SOLAR CELL MODULE
Next Patent: TRANSITION METAL-BASED HETEROGENEOUS CARBONYLATION REACTION CATALYST AND METHOD FOR PRODUCING LACTON...
Next Patent: TRANSITION METAL-BASED HETEROGENEOUS CARBONYLATION REACTION CATALYST AND METHOD FOR PRODUCING LACTON...